Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

14.05USD
26 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$14.05
Open
$14.30
Day's High
$14.50
Day's Low
$13.98
Volume
123,414
Avg. Vol
150,771
52-wk High
$18.00
52-wk Low
$9.48

VNDA.OQ

Chart for VNDA.OQ

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 1.47
Market Cap(Mil.): $625.96
Shares Outstanding(Mil.): 44.55
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.30 -- --
ROI: -9.38 -8.48 -5.42
ROE: -10.59 -11.31 -4.68

BRIEF-Vanda and UCSF announce license agreement for CFTR activators and inhibitors

* Vanda and UCSF announce license agreement for CFTR activators and inhibitors

Mar 29 2017

BRIEF-Point72 Asset Management reports 5 pct passive stake in Vanda Pharmaceuticals as of Feb 15 - SEC Filing

* Point72 Asset Management Reports 5 pct passive stake in Vanda Pharmaceuticals Inc as of Feb 15 - SEC Filing Source text: [http://bit.ly/2lnm4r7] Further company coverage:

Feb 16 2017

BRIEF-Vanda Pharmaceuticals says 2016 total revenues are expected to be nearly $146 mln

* Vanda Pharmaceuticals Inc - 2016 total revenues are expected to be approximately $146 million

Jan 09 2017

More From Around the Web

Competitors

Earnings vs. Estimates